SPG21 Antikörper (N-Term)
Kurzübersicht für SPG21 Antikörper (N-Term) (ABIN5671445)
Target
Alle SPG21 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Sequenz
- GTVPLKKIIV DDDDSKIWSL YDAGPRSIRC PLIFLPPVSG TADVFFRQIL
-
Aufreinigung
- Affinity purified
-
Immunogen
- The immunogen is a synthetic peptide directed towards the N terminal region of Human SPG21
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
- SPG21 (Spastic Paraplegia 21 (SPG21))
-
Andere Bezeichnung
- SPG21
-
Hintergrund
-
The protein encoded by this gene binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. Mutations in this gene are associated with autosomal recessive spastic paraplegia 21 (SPG21), also known as mast syndrome. Alternative splicing results in multiple transcript variants.
Alias Symbols: MAST, ACP33, GL010, BM-019
Protein Size: 281 -
Gen-ID
- 51324
-
NCBI Accession
- NM_001127889, NP_001121361
Target
-